News
-
Israeli phamaceutical company Kamada Ltd announced that it has received Russian and Australian patents related to its inhaled alpha-1 antitrypsin (AAT) for the treatment of lung diseases. Russian Patent No. 2472524 is titled “Alpha-1 Antitrypsin… Read more . . .
-
Italian aerosol device and filling machine company Coster Pharma has announced that its Type 3 Drug Master File (DMF) for two of its MDI valves to the FDA has been issued the DMF number 26960.… Read more . . .
-
Weeks after the conclusion of RDD Europe 2013 in Berlin, organizers RDD Online and Aptar Pharma are still wrapping up logistical loose ends and analyzing delegate feedback, says Pierre Carlotti of Aptar Pharma. . .… Read more . . .
-
Civitas Therapeutics has received a $1 million grant from The Michael J. Fox Foundation for Parkinson’s Research for development of CVT-301 inhaled L-dopa for the treatment of motor fluctuations in Parkinson’s disease patients, the company… Read more . . .
-
Teva has announced that it will acquire inhaled drug developer MicroDose Therapeutx for $40 million up front plus up to $125 million in development and regulatory milestone payments, as well as sales milestone payments and… Read more . . .
-
Shareholders of Elan Corporation have rejected the company’s $1 billion deal for royalties from Theravance inhaled drugs, including the Breo and Anoro Ellipta DPIs. Anticipating the result from the Theravance vote, Elan announced on June… Read more . . .
-
So many shareholders have already voted against Elan’s proposed $1 billion deal for royalties from Theravance inhaled drug products, says Royalty Pharma, that the proposal is unlikely to pass at the upcoming meeting of Elan… Read more . . .
-
OINDP device maker Aptar Pharma has added Chinese, French, German and Spanish versions to its English-language website and plans to add additional languages, including Portuguese, in 2014. According to the company, web traffic has grown… Read more . . .
-
AstraZeneca has announced today that it will acquire 100% of the shares of inhaled drug developer Pearl Therapeutics for $560 million, plus up to $450 million in milestone payments and an additional $140 million if… Read more . . .
-
Hovione has announced the appointment of Justin Hughey, who was most recently Director of Research for Enavail to head its US Particle Design sciences at our site in New Jersey. The company says that it… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK